U.S. Stock Futures Steady as Oil Tops $100 Ahead of Inflation Data 
Zara Owner Inditex Sales Rise 9% in August 
Gold Prices Steady as Hot PPI Boosts Fed Rate Hike Bets 
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
UK Businesses Urge Government to Cut Electricity Levies 
Longsys Raises $903 Million in Hong Kong IPO as Shares Debut Flat 
US Bans Canadian Alcohol, Motorcycles as Trade War Escalates 
Enflame Shares Surge 200% in Shanghai AI Chip Debut 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Trump Signs Order to Cut Routine Childhood Vaccines 
Trump Threatens Bombardier U.S. Sales Ban 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Google Revamps EU Search Results to Meet DMA Rules 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
Add as a preferred source on Google
Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have developed a wearable green organic light-emitting diode (OLED) with a 470-nanometer (nm) wavelength that can cure jaundice in infants.
The OLED provides sufficient power for jaundice treatment even at low voltage, durability for over 100 hours of operation, a low operating temperature of less than 35 Celsius degrees, and flexibility that can endure over 1,000 bends at a 2 mm radius of curvature.
The bilirubin level of the infants’ serum reaches 12 milligrams per decilitre (mg/dL) within three hours of being exposed to the OLED, indicating the completed treatment of jaundice.
Unlike existing light-emitting diode (LED)-based jaundice treatment devices currently used at hospitals, the OLED showed uniform and effective treatment functions.
